LY-266111

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLY-266111
Drug Alias NameLY-266111
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSteroid 5 alpha reductase inhibitors
TargetsSteroid 5 alpha reductase
Therapy Area/IndicationsProstatic Hyperplasia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsProstatic Hyperplasia

Other Information

ATC CodeN/A
Related LinksN/A